Aptevo Therapeutics Inc. financial data

Symbol
APVO on Nasdaq, APVTW on OTC
Industry
Pharmaceutical Preparations
Location
2401 4 Th Ave., Suite 1050, Seattle, Washington
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 275 % -28.1%
Debt-to-equity 99.8 % +34%
Return On Equity -219 % -337%
Return On Assets -110 % -307%
Operating Margin -920 % -428%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.5M shares +224%
Common Stock, Shares, Outstanding 673K shares -90.7%
Entity Public Float 11M USD -38.9%
Common Stock, Value, Issued 66K USD +34.7%
Weighted Average Number of Shares Outstanding, Basic 687K shares +330%
Weighted Average Number of Shares Outstanding, Diluted 687K shares +330%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.11M USD -74.7%
Research and Development Expense 16.7M USD -2.87%
General and Administrative Expense 11.4M USD -16.1%
Operating Income (Loss) -28.1M USD +8.71%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -18.7M USD -366%
Net Income (Loss) Attributable to Parent -27M USD -246%
Earnings Per Share, Basic -28.8 USD/shares -240%
Earnings Per Share, Diluted -28.8 USD/shares -240%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.3M USD -59.5%
Other Assets, Current 691K USD -56.3%
Assets, Current 12.1M USD -57.6%
Property, Plant and Equipment, Net 789K USD -38.6%
Operating Lease, Right-of-Use Asset 4.77M USD -8.35%
Other Assets, Noncurrent 68K USD -90.9%
Assets 17.6M USD -49.6%
Employee-related Liabilities, Current 1.61M USD +157%
Liabilities, Current 6.3M USD +8.64%
Operating Lease, Liability, Noncurrent 5.21M USD -11.6%
Other Liabilities, Noncurrent 14K USD
Liabilities 11.5M USD -1.6%
Retained Earnings (Accumulated Deficit) -230M USD -13.3%
Stockholders' Equity Attributable to Parent 6.1M USD -73.8%
Liabilities and Equity 17.6M USD -49.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.65M USD -246%
Net Cash Provided by (Used in) Financing Activities 6M USD
Net Cash Provided by (Used in) Investing Activities -29K USD +95.9%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 673K shares -90.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.65M USD -347%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.3M USD -30.1%
Deferred Tax Assets, Valuation Allowance 53.2M USD +8.36%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 54.2M USD +7.98%
Operating Lease, Liability 6.08M USD -5.9%
Depreciation 600K USD -33.3%
Payments to Acquire Property, Plant, and Equipment 29K USD -95.9%
Lessee, Operating Lease, Liability, to be Paid 8.72M USD -11.6%
Property, Plant and Equipment, Gross 14.5M USD 0%
Operating Lease, Liability, Current 700K USD +16.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.38M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.38M USD +20%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.64M USD -22.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.38M USD 0%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 15M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 344K USD +199%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 106K USD -40.4%
Deferred Tax Assets, Net of Valuation Allowance 1.03M USD -8.63%
Share-based Payment Arrangement, Expense 2M USD -5.62%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%